Advanced Catheter Therapies
Advanced Catheter Therapies (ACT) develops innovative medical devices, notably the Pressana Occlusion Perfusion Catheter (OPC), which is used for targeted drug delivery in peripheral arterial disease treatment. The company focuses on R&D, licensing, and has received FDA clearances and patents. It aims to improve treatment control, safety, and efficacy for vascular conditions.
Industries
Nr. of Employees
small (1-50)
Advanced Catheter Therapies
Patents
Products
Occlusion perfusion catheter for localized liquid therapy
A catheter system that creates an isolated arterial perfusion chamber using proximal and distal occlusion balloons and a center balloon to enable targeted infusion, controlled circulation and evacuation of liquid therapeutic agents with intrachamber pressure monitoring and radiopaque markers for imaging-guided placement.
Occlusion perfusion catheter for localized liquid therapy
A catheter system that creates an isolated arterial perfusion chamber using proximal and distal occlusion balloons and a center balloon to enable targeted infusion, controlled circulation and evacuation of liquid therapeutic agents with intrachamber pressure monitoring and radiopaque markers for imaging-guided placement.
Services
Licensing of catheter-based liquid delivery technology and formation of distribution partnerships to commercialize the device.
Licensing of catheter-based liquid delivery technology and formation of distribution partnerships to commercialize the device.
Expertise Areas
- Endovascular liquid drug delivery
- Peripheral arterial disease treatment (below-the-knee applications)
- Catheter-based device design and development
- Clinical evidence generation and peer-reviewed research
Key Technologies
- Occlusion balloon perfusion systems
- Isolated intravascular perfusion chambers
- Fiberoptic intravascular pressure sensing
- Radiopaque marker localization
News & Updates
The Pressana OPC has received three FDA 510(k) clearances, enabling its use in peripheral arterial disease treatment.
The company holds multiple patents related to the Pressana OPC device and its applications.
The company has published research on the precision delivery of liquid therapy into arteries using the Pressana OPC.
The Pressana OPC has received three FDA 510(k) clearances, enabling its use in peripheral arterial disease treatment.
The company holds multiple patents related to the Pressana OPC device and its applications.
The company has published research on the precision delivery of liquid therapy into arteries using the Pressana OPC.